Et Si On Parlait Tubes Pdf Reader Average ratng: 6,5/10 9467reviewsDownload free Adobe Acrobat Reader DC software for your Windows, Mac OS and Android devices to view, print, and comment on PDF documents. Download Body Safety Training Program Free.The global standard for reliably viewing PDF documents Excellent PDF Reader is trusted leader for reliably viewing and interacting with PDF documents across platforms and devices. Install the PDF Reader mobile app to work with PDF documents on your Windows Phone. Features: 1.Quickly open PDF documents from the web 2.Search text to find specific information 3.Select single page or continuous scroll modes 4.Easily zoom in/out on text or images for a closer view 5.Download documents on your phone 6. Quickly navigate through large documents using thumbnails 7.Easily select and delete multiple documents 8.Navigate through document using prev page/next page/go to page buttons 9.Bookmarks (favorites) 10.Stream over WiFi or 2.5/3G 11.Very small app (less than 2Mb!) and much more Updates are coming soon.

• Coin Auction Search

Learning of novel information, including novel taste, requires activation of neuromodulatory transmission mediated, for example, by the muscarinic acetylcholine receptors (mAChRs) in relevant brain structures. In addition, drugs enhancing the function of mAChRs are used to treat memory impairment and decline. However, the mechanisms underlying these effects are poorly understood. Here, using quantitative RT-PCR in Wistar Hola rats, we found quinone reductase 2 (QR2) to be expressed in the cortex in an mAChR-dependent manner. QR2 mRNA expression in the insular cortex is inversely correlated with mAChR activation both endogenously, after novel taste learning, and exogenously, after pharmacological manipulation of the muscarinic transmission. Moreover, reducing QR2 expression levels through lentiviral shRNA vectors or activity via inhibitors is sufficient to enhance long-term memories.

We also show here that, in patients with Alzheimer's disease, QR2 is overexpressed in the cortex. It is suggested that QR2 expression in the cortex is a removable limiting factor of memory formation and thus serves as a new target to enhance cognitive function and delay the onset of neurodegenerative diseases.SIGNIFICANCE STATEMENT We found that: (1) quinone reductase 2 (QR2) expression is a muscarinic-receptor-dependent removable constraint on memory formation in the cortex, (2) reducing QR2 expression or activity in the cortex enhances memory formation, and (3) Alzheimer's disease patients overexpressed QR2. We believe that these results propose a new mechanism by which muscarinic acetylcholine receptors affect cognition and suggest that inhibition of QR2 is a way to enhance cognition in normal and pathological conditions. IntroductionSome sensory experiences do not form stable memories, whereas others form short-term memories, which last minutes to hours, and long-term memories, which can guide animal behavior for many hours up to a lifetime (;;; ).

It is suggested that experiences important for an animal's survival create more stable memories in evolutionary-dependent mechanisms (; ). The underlying mechanisms controlling memory strength are not well understood. Here, we used taste learning to identify constraints imposed on cortical-dependent learning, the brain area assumed to store long-term memories in the mammalian brain (;; ).The sense of taste is critical in allowing the animal to differentiate between nutritious and harmful food such as poison. Animals, including humans, are naturally neophobic; they tend to initially consume only small amounts of any novel tastant. Animals may develop a long-term memory of a given novel taste, including its safety, after exposure to even a small amount of the taste (; ).Novel taste learning is correlated with prolonged release of acetylcholine (Ach) in the insular cortex (IC) (; ). ACh activates nicotinic and muscarinic receptors and the latter are necessary for novel taste learning.

The cholinergic system plays a role in various cognitive processes including attention, learning, and memory (; ) and is essential for learning by responding to the novelty of the stimulus. The cholinergic system also play a role in neurological diseases involving dementia, such as Alzheimer's disease (AD). Pharmaceuticals used to treat dementia often contain a cholinesterase inhibitor.After a preliminary screening for differential mRNA expression in the IC of animals that learned negative or positive tastes, we focused our study on quinone reductase 2 (QR2), one of two primary quinone reductases found in mammals: QR1 and QR2 (or NQO1 and NQO2, respectively). QR2 is expressed throughout the cortex and hippocampus and is primarily found in the cytoplasm of neurons.

Interestingly, the majority of the research relating to the interaction between QR2 and disease has been focused on its role in skin cancer and malaria (;;; ). Recently, QR2 overexpression has been correlated with a variety of neurological diseases, including schizophrenia (; ), Parkinson's disease (; ), and AD. In this study, we hypothesize that QR2 expression is a memory constraint that can be removed behaviorally by novel experience or pharmacologically by acetylcholine esterase inhibitors. Novel taste learning.On the learning day, the experimental group received 2 pipettes, each containing 10 ml of a novel taste solution, saccharin (0.1% w/v; Sigma-Aldrich), for 20 min. The control group received two pipettes, each containing 10 ml of water for 20 min. After exposure to the novel taste, the animals went through 2 d of water restriction during which they received 2 pipettes each filled with 10 ml of water for 20 min each day.

On the third day, all of the rats were given two pipettes, each containing 10 ml of water, as well as two pipettes, each containing 10 ml of the novel taste solution previously given to the experimental group. Comparisons between the groups were conducted through the evaluation of the preference indexes (PIs). The PI was calculated by the following equation: (total novel taste solution ingested/(novel taste solution ingested + water ingested)). 100. The higher the PI, the more the rat preferred the novel taste.

Conditioned taste aversion.On the learning day, the experimental group received 2 pipettes, each containing 10 ml of a novel taste solution, saccharin (0.1% w/v), for 20 min. The control group received two pipettes, each containing 10 ml of water, for 20 min. Forty minutes after the drinking period, both groups were injected with LiCl (prepared in double-distilled water (DDW, 2% bodyweight, i.p.).After the learning day, the animals went through 2 d of water restriction during which they received two pipettes, each filled with 10 ml of water, for 20 min each day. On the third day, all of the rats were given two pipettes each containing 10 ml of water, as well as two pipettes each containing 10 ml of the novel taste liquid previously given to the experimental group. Comparisons between the groups were conducted through the evaluation of the aversion indexes (AIs).

The AI was calculated by the following equation: (total water ingested/(novel taste solution ingested + water ingested)). 100. The higher the AI, the more the rat learned the negative association of the taste. MRNA quantification.For RNA extraction, the RNeasy lipid tissue kit (QIAGEN) was used according to the manufacturer's instructions.

RNA concentration and purity were evaluated using Nanodrop (Thermo Scientific Nanodrop 2000).A high-capacity reverse transcription kit (ABI) was used according to the manufacturer's instructions for cDNA synthesis. The reaction was performed in a total volume of 20 μl using 1 μg of RNA as a template.qRT-PCR was performed in a total volume of 10 μl using 10 ng of cDNA and the following TaqMan assays (Applied Biosystems): QR2 (Rn01434728g1), NAD(P)H dehydrogenase quinone 1 (NQO1) (RN00566528m1), glyceraldehyde-3-phosphate dehydrogenase, GAPDH (Rn01775763g1). Reactions were performed in accordance with the manufacturer's instructions.Real-time PCR analysis was performed using the PCR System STEP-ONE plus (Applied Biosystems). Relative mRNA levels were calculated using the ΔΔC t method using GAPDH as a normalizing gene as follows:ΔΔ C t = ( C t(gene of interest) − Ct(GAPDH)) of the untreated group − ( C t(gene of interest) − Ct(GAPDH)) of the treated group and the fold increase = 2 −ΔΔCt.

Microarray experiment and data analysis.Affymetrix GeneChip RaGene 1.1 ST v1 array was used for gene expression analysis in accordance with the manufacturer's instructions (Affymetrix). Microarray analysis was performed on CEL files using the Partek Genomics Suite. Data were normalized and summarized with the robust multiaverage method and expression intensities were obtained in log2 scale. One-way ANOVA was applied. Venn diagrams were formed using the Partek Genomics Suite. Only genes that showed a strong trend of being differentially expressed with a fold change difference of ≥1.25 were represented in the Venn diagrams.

Micro-infusion.Rats were anesthetized with Equithesin (0.45 ml/100 g; 2.12% w/v MgSO 4, 10% v/v ethanol, 39.1% v/v 1,2,-propranolol, 0.98% w/v sodium pentobarbital, and 4.2% w/v chloral hydrate) and restrained in a stereotactic apparatus (Stoelting) and guide stainless steel cannulae (23 gauge) were implanted bilaterally into the GC (anterior–posterior, 1.2 mm; dorsal–ventral, 6.5 mm; lateral, 5.5 mm). The cannulae were positioned using acrylic dental cement and secured by two skull screws. A stylus was placed in the guide cannulae to prevent clogging. After surgery, animals were allowed to recover for 1 week before being subjected to experimental manipulations.

On the experiment day, the stylus was removed from the guide cannula and a 28 gauge injection cannula extending from the tip of the guide cannula was placed carefully. The injection cannula was connected via PE20 tubing to a Hamilton microsyringe driven by a micro-infusion pump (CMA/100; Carnegie Medicine).

Micro-infusion was performed bilaterally in 1 μl of inhibitor per hemisphere delivered over 1 min. The injection cannula was left in position before withdrawal for an additional 1 min to minimize dragging of the injected liquid along the injection tract. To avoid lateral bias, order of hemisphere injection was randomized. After the microsurgery, animals were injected with 0.01 ml/100 g of amoxicillin (15% bodyweight s.c.) daily for 3 d and allowed to recuperate for 1 week. Lentiviral vectors and infection.Three clones containing short hairpin RNA (shRNA) constructs directed against QR2, as well as a scrambled shRNA sequence clone, were obtained from Sigma-Aldrich. The clones were chosen based on a BLAST evaluation for matching and specificity to QR2. After further evaluation of these clones as explained below, the TRCN clone was selected for further use.

The clone sequence was as follows: 5′-CCGGCAGTCACTGTGTCTGATTTATCTCGAGATAAATCAGACACAGTGACTGTTTTTG-3′.The U6-promoter-regulated shRNA sequences were each subcloned into the lentiviral (LV) plasmid pFUGW for coexpression of shRNA driven by the U6 promoter with EGFP under control of the CMV promoter. The LV was produced according to the method described by.In brief, the cassettes containing the shRNA sequences, EGFP, and the promoters were transfected into the 293FT cell line (Invitrogen) and allowed to express and form particles for 48 h. This was then collected and then purified and concentrated though a series of centrifugation steps.

The resulting LVs were then dissolved in sterile PBS and stored at −80°C until use.LVs were stereotaxically injected into the IC in anesthetized rats using a 23 gauge stainless steel injector attached to a stereotactic infusion pump, rats received bilateral 1 μl of LVs over 10 min per hemisphere. The injector was left in place for 5 min before and after infusion to minimize fluid retraction. After the microsurgery, animals were subcutaneously injected with 0.01 ml/100 g of amoxicillin and given 7 d to recover and for the LVs to express. Generation of primary cortical cell cultures and evaluation of shRNA clones.Cortical cell cultures were prepared as described previously.

Briefly, cortex regions were dissected from 1- to 2-d-old WSH rats, dissociated by trypsin treatment and DNase treatment, followed by trituration with a siliconized Pasteur pipette, and then plated onto 6-well plates coated with polyethylenimine (Sigma-Aldrich). Seeding culture medium consisted of MEM (Invitrogen without phenol red for microscopy), 20 m m glucose (Sigma-Aldrich), gentamycin sulfate 5 μg/ml (Sigma-Aldrich), 25 mg/L insulin (Sigma-Aldrich), 2 m m l-glutamine (Sigma-Aldrich), 5–10% fetal bovine serum (Sigma-Aldrich), and 10% NU serum (Becton Dickinson Labware). Cultures were maintained at 37°C in a 95% air/5% CO 2 humidified incubator and culture medium was replaced to feeding medium containing MEM (σ) 20 m m glucose (Sigma-Aldrich), gentamycin sulfate 5 μg/ml (Sigma-Aldrich), and 2% B-27 (Invitrogen), and 0.5 m m l-glutamine supplement (Invitrogen) every 7 d.The clones were then each evaluated in the primary cortical cell cultures. After the application of the three different clones, as well as a scrambled version that acted as a control, the cultures were analyzed for QR2 mRNA expression.

We also evaluated changes in NQO1 mRNA expression as a way of evaluating specificity. None of the clones led to changes in NQO1 mRNA expression levels and all led to a decrease in QR2 mRNA expression levels. We selected the clone that was the most efficient, TRCN. Perfusion and fixation.The animals were deeply anesthetized with an overdose (10 mg/100 g) of sodium pentobarbital and then perfused through the left ventricle, first with ice-cold 0.01 m PBS solution and then with a fixative containing 4% paraformaldehyde (PFA) in 0.01 m PBS, pH 7.4, for 15 min. The brains were removed and postfixed in the same solution overnight. They were then stored in a 30% sucrose and 1% PFA in 0.01 m PBS for 4 d. After postfixation, brains were frozen at −80°C until sectioning by cryostat.

Immunohistochemistry.Coronal 30 μm brain sections from +1.2 bregma were sliced with a cooled cryostat (Leica CM 1850). Slices were washed twice with 0.01 m PBS, and nonspecific antibody binding was blocked with 1.2% (w/v) normal goat serum (NGS) in 0.01 m PBS containing 0.5% Triton X-100 for 3 h at room temperature (RT). The sections were incubated with monoclonal mouse anti-NeuN antibody (Millipore) diluted 1:100 in 0.01 m PBS and 0.2% (w/v) NGS solution for 24 h at 4°C with gentle shaking.

After 3 washes in 0.01 m PBS, sections were incubated in secondary antibody Alexa Fluor 594 goat anti-mouse IgG (H+L) antibody (Invitrogen) in 1:400 dilution prepared in 0.2% (w/v) normal goat serum in 0.01 m PBS for 2 h at RT. After 2 PBS 0.01 m washing steps, nuclei were stained by incubating the sections with Hoechst 33258 diluted 1:5000 in PBS 0.01 m. Sections were mounted onto Super Frost-coated slides with Slow Fade antifade medium (Invitrogen). Slides were kept in the dark at 4°C before image acquisition and analysis. MRNA quantification of the human samples.For the human samples, total RNA (1 μg) from the syperior frontal gyrus (Bm8) was reverse transcribed using ImpromII (Promega) with random hexamers (MBI Fermentas). Real-time PCR was performed in a total volume of 10 μl using TaqMan universal PCR master mix (Applied Biosystems) using 2 μl of cDNA and gene-specific “assay on demand” TaqMan reactions (Applied Biosystems).

Real-time PCRs were performed in duplicate using the ABI PRISM StepOne plus Sequence Detector (Applied Biosystems) under the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Threshold cycle (Ct) values of the examined gene of interest (QR2, Hs01056948m1) were normalized to the Ct values of two housekeeping genes GUSB and IPO8 (Hs99999908-m1, Hs00183533-m1 respectively) in the AD and aged matched control groups. Relative mRNA quantities were calculated for each sample separately using the 2 −ΔCt formula and mRNA RQ for the test group (AD) was calculated using the 2 −ΔΔCt formula. Statistical analysis were performed using 2 −ΔCt values. CTA learning leads to a reduction in QR2 mRNA in the ICTo identify transcriptional changes after associative taste learning, we used the conditioned taste aversion (CTA) paradigm, subserved by the IC A; (; ), combined with microarray technology (Affymetrix rat gene 1.1 st arrays). Among the differentially transcribed mRNAs, we observed an ∼50% reduction in QR2 mRNA expression in the CTA group compared with the control group exposed to the unconditioned stimulus (UCS; LiCl 0.15 m, i.p.), but not the conditioned stimulus per se (CS; novel taste, saccharin; B).

CTA induces a reduction in QR2 mRNA expression in the IC. A, Schematic representation of the experiment. The CTA paradigm was performed on rats exposed to saccharin and LiCl (CS and UCS, respectively) and results were compared with exposure to either saccharin or LiCl. B, Venn diagram representing the differentially expressed genes that passed the cutoff of a fold change of at least 1.25. L, Rats that received only LiCl; S, rats that received only saccharin; C, rats that received saccharin followed by LiCl. QR2 ( NQO2) is one of the genes differentially expressed in response to CTA. C, Schematic representation of the CTA learning paradigm.

D, Pairing of the saccharin (CS) with the malaise-inducing LiCl injection (UCS) causes a reduction in QR2 mRNA expression in the insular cortex compared with the control group exposed only to the UCS ( n = 10).Having decided to focus on QR2, we validated the microarray results using the qRT-PCR method, observing an ∼45% reduction in QR2 mRNA expression in the IC in the CTA group compared with the control group ( C, D; unpaired Student's t test, t 10.39 = 4.3, n = 10, p = 0.001). CTA has both a component of novel taste learning (CS) and a component of associative learning (UCS); we hypothesized that learning a novel taste, as measured by the decrease in neophobic response (i.e., a form of incidental learning that can be measured by increased consumption of a given taste over time) without the negative association component, would lead to a decrease in QR2 mRNA expression in the IC. Novel taste learning leads to a decrease in QR2 mRNA expressionWe evaluated changes in QR2 mRNA expression in the IC 3 h after the learning period ( A). Consistent with our hypothesis, we observed a decrease in QR2 mRNA expression in the group that learned the novel taste compared with the group that received a familiar taste and did not undergo a learning paradigm ( B; unpaired Student's t test, t 11.767 = 4.3, n ≥ 10, p = 0.001).

This novel taste learning-induced decrease is both specific to the relevant cortical area (IC, C; unpaired Student's t test, t 13.89 = 0.1, n = 8, p = 0.887) and to the QR2 oxi-reductase ( D; unpaired Student's t test, t 11.27 = −0.7, n = 8, p = 0.447) because its homologous enzyme, NQO1, is unaffected. Novel taste learning induces a reduction in QR2 mRNA expression in the IC.

A, Schematic representation of the novel taste learning paradigm. B, Novel taste learning leads to a significant decrease in QR2 mRNA expression in the IC (control, n = 12; test, n = 10). C, QR2 mRNA expression in the occipital cortex of the animals that underwent the novel taste learning paradigm is unaffected ( n = 8). D, mRNA expression of NQO1 was evaluated in the IC in the animals which underwent the novel taste learning paradigm to determine the effect of novel taste learning on the expression of the other primary oxireductase. The results show that novel taste learning has no effect on NQO1 mRNA expression in the IC ( n = 8).The novel taste learning-induced decrease in expression levels of QR2 mRNA may result from two possible mechanisms.

First, drinking itself leads to higher levels of QR2 mRNA expression in the IC and this increase is prevented when the drinking involves novel taste learning. Second, the novelty component of the novel taste leads to a decrease in QR2 mRNA expression in the IC.

To dissociate between these possibilities, we used a group of animals that were water deprived for 24 h to determine the baseline expression levels of QR2, in addition to the other two groups, which were exposed to either a novel taste or a familiar taste ( A). The results show that QR2 mRNA expression levels in the IC in the animals in the baseline group were similar to those of the animals in the group that received the familiar taste. This suggests that novel taste learning, and not drinking itself, induces a decrease in QR2 mRNA expression in the IC B; one-way ANOVA F (2,15) = 3.9, n = 6, p = 0.044, Fisher's LSD post hoc test (novel/water deprived) p = 0.029, Fisher's LSD post hoc test (novel/familiar) p = 0.03. QR2 mRNA expression is inversely correlated with novelty in the IC. A, Experimental design to evaluate baseline levels of QR2 mRNA expression in the IC. B, Baseline levels of QR2 mRNA in the IC are high and are significantly reduced after exposure to novel taste ( n = 6). C, Experimental design to evaluate the effect of the familiarization of the animals to saccharin.

D, Novel taste consumption significantly reduces QR2 mRNA expression, whereas prolonged familiarization with a novel taste results in high QR2 mRNA levels, similar to those of a familiar taste ( n = 6).Novel sensory input is salient information that induces release of different neuromodulators in the relevant brain structure. We hypothesized that the change in expression of QR2 is not due to the specific coding of the chemical information, but rather it specifically reflects the novelty itself. To evaluate this, we used a group that was familiarized to saccharin in addition to the other two groups, which were exposed to either a familiar taste (water) or a single exposure to saccharin (a novel taste; C). The rats familiarized with saccharin displayed no reduction in QR2 mRNA expression in the IC, demonstrating that the change in expression was due to the learning of the novel information D; one-way ANOVA F (2,15) = 4.6, n = 6, p = 0.028, Fisher's LSD post hoc test (novel/familiar saccharin) p = 0.023, Fisher's LSD post hoc test (novel/familiar water) p = 0.016.Interestingly, basal levels of QR2 mRNA expression in the IC appear to vary between two fixed floor and ceiling values. Novel taste learning reduces QR2 mRNA expression levels to the lower limit and thus reduces the variance in its expression. Indeed, Levene's test for homogeneity of variances revealed that the variation in expression levels of QR2 mRNA after novel taste learning was smaller compared with exposure only to the UCS ( A; F (1,18) = 11.7, n = 10, p = 0.0037), exposure to water as a familiar taste ( B; F (1,20) = 15.5; control, n = 12; test, n = 10, p = 0.001), water deprivation ( C; F (1,10) = 6.6, n = 6, p = 0.028), or exposure to saccharin as a familiar taste ( D; F (1,10) = 10.4, n = 6, p = 0.009). Novel taste learning reduces the variance in QR2 mRNA expression in the IC.

To better illustrate the high level of variance of QR2 mRNA expression in the IC in the control groups and the resulting reduction in that variance after novel taste learning, we show here QR2 mRNA expression in the IC from individual animals corresponding to the results shown above in. As can be seen from A, which corresponds to B ( n = 10); B, which corresponds to B (control, n = 12; test, n = 10); C, which corresponds to B ( n = 6); and D, which corresponds to D ( n = 6); novel taste learning not only leads to a reduction in QR2 mRNA expression in the IC, but also leads to a significant reduction in the variance of QR2 mRNA expression. QR2 mRNA expression is mAChR dependentAs mentioned above, it is well established in the literature that the activation of mAChR is necessary for learning new information (; ), including novel taste learning. We corroborated these findings ( A, B; one-way ANOVA F (2,20) = 46.9; control, n = 8; scopolamine, n = 8; eserine, n = 7, p ≪ 0.001), verifying that blocking mAChR through the use of an mAChR antagonist, scopolamine (2 mg/kg, i.p.), prevents the formation of a novel taste memory (Fisher's LSD post hoc test p ≪ 0.001) while increasing the amount of ACh in the system using eserine, an ACh esterase inhibitor and thus a functional mAChR agonist (1 mg/kg, i.p.), enhances the memory of a novel taste (Fisher's LSD post hoc test p = 0.022).

In addition, it has been shown that inhibiting QR2 activity can lead to partial recovery from the negative effects brought on by the application of scopolamine (an mAChR antagonist) in old animals, a model for aging. We therefore hypothesized that QR2 downregulation after learning novel sensory information in the cortex is mAChR dependent. QR2 mRNA expression is mediated by mAChR activity. A, Schematic representation of the experiment. Rats were injected with scopolamine, eserine, or vehicle before being exposed to a novel taste (saccharin). The animals were then subjected to a taste preference test to assess learning performance.

B, Blockade of the mAChR during novel taste learning prevents novel taste memory formation, as can be seen from the significantly lower PI in the group injected with scopolamine compared with the control group. Furthermore, increased mAChR activation during novel taste learning leads to enhanced learning of the novel taste, as can be seen from the higher PI in the group injected with eserine compared with the control group (control, n = 8; scopolamine, n = 8; eserine, n = 7). C, Experimental design to determine the effect of preventing mAChR activation on QR2 mRNA expression in the IC after novel taste learning D, Injection with mAChR antagonist scopolamine (2 mg/kg, i.p.) before exposure to novel taste abolishes the decrease in QR2 mRNA.

Administration of mAChR agonist eserine (1 mg/kg, i.p.) before exposure to novel taste does not lead to further decrease in QR2 mRNA levels (vehicle familiar, n = 21; vehicle novel, n = 12; scopolamine novel, n = 6; eserine novel, n = 6). E, Experimental design to determine the effect of pharmacologically induced activation of mAChR on QR2 mRNA expression in the IC. F, The novel taste-induced decrease in QR2 mRNA expression in the insular cortex can be achieved even in the absence of the novel taste in animals injected with eserine. However, administration of scopolamine to animals given a familiar taste does not result in increased QR2 mRNA levels compared with baseline (vehicle familiar, n = 21; vehicle novel, n = 12; scopolamine familiar, n = 8; eserine familiar, n = 7).We first examined the effect of preventing mAChR activation ( C).

These results demonstrate that the reduction in QR2 mRNA expression seen after novel taste exposure (Fisher's LSD post hoc test p ≪ 0.001) is precluded through the blockade of mAChR using scopolamine (2 mg/kg, i.p.; Fisher's LSD post hoc test, p = 0.001), indicating the necessity of mAChR activation to regulate QR2 expression ( D; one-way ANOVA F (3,41) = 13; vehicle + familiar taste, n = 21; vehicle + novel taste, n = 12; scopolamine + novel taste, n = 6; eserine + novel taste, n = 6, p ≪ 0.001). The animals that underwent the novel taste learning paradigm and were given eserine (1 mg/kg, i.p.) to increase ACh availability, did not have further decreased QR2 mRNA expression levels compared with the control group (Fisher's LSD post hoc test p = 0.655). Decreasing QR2 mRNA expression enhances novel taste learningAfter our results that novel taste learning leads to an mAChR-dependent decrease in QR2 mRNA expression in the IC and the well documented role of ACh in memory enhancement (;;;; ), we hypothesized that decreasing QR2 expression is a mechanism by which mAChR exerts its cognitive enhancement effect. Specifically, we hypothesized that decreasing QR2 mRNA expression in the IC would enhance the animal's ability to form taste memories for two reasons. First, we conjectured that if taste learning leads to a decrease in QR2 mRNA expression, then the a priori decrease of QR2 mRNA expression would enhance taste memory. Second, as noted above, QR2 KO mice showed enhanced cognitive function in hippocampal-dependent tasks.To reduce QR2 mRNA expression, we administered a lentiviral vector expressing QR2 shRNA or a scrambled-sequence control vector (scr) stereotaxically into the IC, which we verified through immunohistochemistry ( A).

In addition, we confirmed that there was a reduction QR2 mRNA expression in the IC in both experiments in which we used the injected animals ( B; unpaired Student's t test, t 11.213 = 3.1, scr: n = 12, shRNA: n = 10, p = 0.009; C; unpaired Student's t test, t 9.522 = −3, n = 7, p = 0.015). Verification of injection site and the efficacy of the QR2 shRNA lentiviral vector. A, The injection site was verified through immunohistochemistry, allowing detection of the GFP attached to the shRNA. B, We verified that the injection of the QR2 shRNA for the experiment described in, B and C, was successful in reducing QR2 mRNA expression (scrambled, n = 12; shRNA, n = 10).

C, We verified after the experiment described in, F and G, that the injection of the QR2 shRNA was successful in reducing QR2 mRNA expression (scrambled, n = 12; shRNA, n = 10).We evaluated the performance of the animals injected with the QR2 shRNA vector, compared with those injected with a scrambled-sequence vector, in a novel taste learning paradigm ( A, B). Our results establish that the a priori reduction of QR2 mRNA expression in the IC significantly enhances novel taste learning, but does not affect taste perception ( C; unpaired Student's t test, t 19.911 = −3.7, scr: n = 12, shRNA: n = 10, p = 0.001). Decreasing either QR2 expression or activity enhances positive and negative novel taste learning. A, Structure of lentiviral vectors injected into the IC. Top, Vector containing QR2 shRNA injected to the test group.

Bottom, Scrambled vector injected to the control group. B, Experimental design to determine the effect of reducing QR2 mRNA expression on novel taste memory. C, Animals injected with QR2 shRNA show significantly enhanced learning of the novel taste compared with control (scrambled, n = 12; shRNA, n = 10). D, Experimental design to determine the effect of inhibiting QR2 activity on taste memory.

Animals were injected with QR2 inhibitors S29434 or S26695 (8 mg/kg, i.p.) or saline (control). E, Animals injected with either of the QR2 inhibitors display significantly enhanced learning of the novel taste compared with control ( n = 8). F, Experimental design to determine the effect of reducing QR2 mRNA expression on negative taste memory (CTA).

G, Animals injected with QR2 shRNA show significantly enhanced learning of the negative association of the novel taste compared with control (scrambled, n = 7; shRNA, n = 8). H, Experimental design to determine the effect of inhibiting QR2 activity on negative taste memory (CTA). Animals were injected with QR2 inhibitors S29434 or S26695 (8 mg/kg, i.p.) or saline (control). I, Animals injected with either of the QR2 inhibitors display significantly enhanced learning of the negative association of the novel taste compared with control ( n = 8). Inhibiting QR2 activity enhances novel taste learningNext, we hypothesized that inhibiting QR2 activity would also enhance novel taste learning similarly to inhibition of QR2 mRNA expression with the lentiviral vector. We used two synthetic inhibitors, S29434 and S26695 (;; ), to evaluate this hypothesis ( D). Indeed, animals that received either of the inhibitors performed significantly better in the novel taste learning paradigm E; one-way ANOVA F (2,21) = 14, n = 8, p ≪ 0.001, Fisher's LSD post hoc test (vehicle/S29434) p ≪ 0.001, Fisher's LSD post hoc test (vehicle/S26695) p = 0.003.

Coin Auction Search

Decreasing QR2 mRNA expression or inhibiting QR2 activity enhances negative taste learningTo further demonstrate that reducing QR2 mRNA expression or QR2 activity enhances taste learning, we used a negative form of the taste learning paradigm. We administered the same lentiviral vector expressing QR2 shRNA used above (, A) stereotaxically into the IC. We then evaluated the performance of the animals injected with the QR2 shRNA vector compared with those injected with a scrambled-sequence vector in a CTA learning paradigm ( F). These results demonstrate that the a priori reduction of QR2 mRNA expression in the IC not only enhances positive forms of taste learning, as seen above ( C), but also enhances negative taste learning ( G; unpaired Student's t test, t 12.969 = −3.12, scr: n = 7, shRNA: n = 8, p = 0.009). In addition, animals that were injected with either one of the synthetic inhibitors, S29434 or S26695, when subjected to the CTA learning paradigm ( H), also demonstrated enhanced performance I; one-way ANOVA F (2,21) = 9.1, n = 8, p = 0.0011, Fisher's LSD post hoc test (vehicle/S29434) p = 0.001, Fisher's LSD post hoc test (vehicle/S26695) p = 0.0051. These results confirm that inhibiting QR2 activity enhances both positive and negative cortical-dependent taste learning, as does the reduction of QR2 mRNA expression in the IC.

Decreasing QR2 mRNA expression affects learning but not retrievalWe wanted to ensure that decreasing QR2 mRNA expression levels in the cortex does not enhance newly encoded memories at the expense of previously encoded ones nor cause any encountered stimuli to be treated as novel ones, even if they are familiar. To evaluate this, we performed a retrieval paradigm ( A). The animals underwent a CTA learning paradigm. We then administered the same lentiviral vector expressing QR2 shRNA or control used above stereotaxically (, A). We hypothesized that, if reducing QR2 expression using a lentiviral vector expressing QR2 shRNA would cause the animals to treat all stimuli as novel, then they would not show aversion toward the novel taste.

The animals were then tested to evaluate the aversive memory previously encoded. There was no difference between the groups, indicating that decreasing QR2 mRNA in the IC does not have a negative effect on the ability to recall previously encoded memories ( B; unpaired Student's t test, t 14 = 0.5, scr: n = 7, shRNA: n = 8, p = 0.651). Decreasing QR2 mRNA expression enhances memory formation, but does not affect retrieval. A, Schematic representation of the experiment. The CTA paradigm was performed on rats using saccharin and LiCl. The rats were then injected either with the QR2 shRNA LV or with the scrambled virus and assessed for aversion toward saccharin. They were then exposed to the CTA paradigm for a different taste, NaCl, and then assessed for aversion toward this taste.

B, There was no difference between the groups in retrieval of the memory of saccharin as being aversive. This demonstrates that decreasing QR2 mRNA expression in the IC does not affect previous memories (scrambled, n = 7; shRNA, n = 8). C, The animals injected with the lentivirus containing QR2 shRNA, and therefore with a lower expression of QR2 mRNA in the cortex, performed better on the CTA paradigm (scrambled, n = 7; shRNA, n = 8).We then confirmed that these animals had enhanced taste learning abilities by subjecting them to a second CTA paradigm using NaCl as a novel taste learning paradigm ( A). The animals injected with the lentiviral vector expressing QR2 shRNA performed significantly better than those injected with the scrambled virus ( C; unpaired Student's t test, t 8.862 = −2.3, scr: n = 7, shRNA: n = 8, p = 0.046). These results further confirm that decreasing QR2 mRNA expression in the IC enhances taste learning without affecting previously encoded taste memories or taste recognition.

QR2 mRNA is overexpressed in AD patientsHuman QR2 is very similar to rodent QR2 on the molecular and functional levels. It has been demonstrated that patients with AD overexpress QR2 protein in the hippocampus. We measured cortical QR2 mRNA from AD patients and healthy aged matched controls. AD patients express chronically higher levels of QR2 mRNA in the frontal cortex (Brodmann area 8;; unpaired Student's t test, t 29.041 = 2.2, healthy controls: n = 11, AD patients: n = 27, p = 0.034).

We had no information on the medication regimen of the patients, which may affect correlative measurements. However, one would assume that, if some of the subjects were treated with acetylcholineesterase inhibitors, then the QR2 levels would be decreased rather than increased. DiscussionAfter differential screening of genes with expression that is modulated in the IC of rats that underwent the taste learning paradigm, we demonstrated that the novelty component in novel taste learning leads to and is dependent upon decreased QR2 mRNA expression in the IC. This decrease in QR2 mRNA expression is downstream from mAChR activation.

Furthermore, we have established that the inhibition of QR2 activity or the reduction of QR2 mRNA expression in the IC enhances novel taste learning. This corresponds to previous work in which scopolamine-induced animal models for age-related cognitive deficiencies had a partial recovery of ability to perform in hippocampal-related tasks after their exposure to a QR2 inhibitor. Interestingly, in the current work, we identify a direct link among mAChR activation, QR2 expression, and cortical-dependent cognitive enhancement.Our results have several significant ramifications.

First, QR2 is a constraint on cortical-dependent memory consolidation, which is removed endogenously by novel information that is mediated via an mAChR activation. Moreover, we draw a correlative and causal link between a value of given sensory information (i.e., novelty), activation of mAChR, and reduced expression of QR2 in the relevant cortical area.The physiological function of QR2 in neurons and its mechanism of action are currently unknown, mainly because the endogenous substrates of QR2 remain unknown or in question. Based on the literature, there are few conceivable molecular or cellular theoretical possibilities to explain the effect of QR2 on memory. The first possibility is that QR2 reduces oxidative stress similarly to QR1 (; ). QR2 may affect dopamine by triggering the double reduction of the dopamine quinone, as shown in a study using the model of the developing chick retina. Indeed, QR2 has been shown to protect against neurotoxic o-quinones, free radicals formed during catecholamine metabolism.

As a result, oxidative stress, which is involved in the etiology of age-related cognitive impairment and AD, is reduced.Another possibility is that QR2 interacts with the proteasome machinery. For example, both QR1 and QR2 protect the tumor suppressor p53 against degradation by regulating the ubiquitin-independent proteasomal 20S pathway and QR1 has been shown to accumulate in brains of some AD patients due to defective regulation of E3 ligase STUB1/CHIP. Sma america string sizing tool. Interestingly, both proteasome-mediated protein degradation and protein synthesis are necessary for memory consolidation in a brain-region-specific manner (;;;;;;; ). In a recent study done in SH-SY5Y neuroblastoma cells, the synthesis of Arc/Arg3.1, an immediate early gene necessary for synaptic plasticity, was shown to be increased after mAChR stimulation, whereas proteasomal degradation limited the amount and duration of Arc/Arg3.1 expression. Furthermore, mimicking rapid eye movement sleep epochs in conjunction with application of the mAChR agonist carbachol, a combination associated with long-term synaptic plasticity and memory, generates persistent, maximal ERK-dependent Arc/Arg3.1 expression.

Therefore, this interplay of the cholinergic system and proteasomal machinery may be mediated at least in part via QR2.From a cellular perspective, it is possible that QR2 affects intrinsic properties of neurons and/or synaptic plasticity. However, QR2 KO mice do not show any difference in LTP or LTD in the hippocampus compared with WT littermates.

One must be cautious in ruling out this possibility because this mouse model involves complete prenatal knock-out of QR2, which may lead to developmental compensatory processes to overcome this loss of function mutation. In addition, other protocols to induce LTP/LTD should be tested. Furthermore, it is possible that QR2 levels affect neuronal intrinsic properties to exert its effect on memory processes (, ). A massive effort should be taken to prove or refute the theoretical hypotheses for the downstream effect of QR2 on brain function and learning.

However, our findings draw for the first time a clear link upstream to QR2 expression, that is, the relationship among novel sensory information, QR2 expression in the relevant cortical structure, the muscarinic acetylcholine system, and memory strength.From a clinical perspective, our work opens new possibilities for the treatment of neurodegenerative diseases. The very few known treatments for memory enhancement in neurodegenerative diseases include ACh esterase inhibitors (; ), which have the potential to interfere with other nonrelated physiological processes (; ). The identification of QR2 as a clear downstream target that can explain the enhanced memory effect of ACh esterase inhibitors positions it as a prime new target for memory enhancement. Interestingly, AD patients overexpress QR2 protein and mRNA ( and ). There are numerous factors implicated as being involved in AD, such as TAU pathology, Aβ 42 levels, plaque load, age, and the number of APOE ε4 alleles. Further studies are needed to delineate the relationship between QR2 and these factors.It has also been shown recently that resveratrol, a known QR2 inhibitor , leads to improved memory performance.

Our results, in addition to shedding light on molecular mechanisms underlying endogenous neuromodulatory effects on learning and exogenous pharmacological effects on memory, provide a promising new downstream target for treating cognitive dysfunction in different pathologies ranging from mild cognitive impairment to AD. This work was supported by European Union Seventh Framework Program EUROSPIN (Contract HEALTH-F2-2009-241498 to K.R.), the German-Israeli Foundation DIP (Grant RO3971/1-1 to K.R.), and the Israel Science Foundation (Grant 1003/12 to K.R.). We thank Jean A. Boutin (Pharmacologie Moleculaire et Cellulaire, Institut de Recherches Servier for the kind gift of QR2 inhibitors, S29434, and S26695); Vahram (Harry) Haroutunian and Joeseph Buxbaum (Mt.

Sinai School of Medicine, New York, New York) for the human brain tissue; members of the K.R. Laboratory for support, specifically David Levitan and Chinnakkaruppan Adaikkan for the numerous discussions we had regarding this work and their invaluable advice; and Paul Skehel and Shunit Gal-Ben-Ari for critical review of the manuscript.The authors declare no competing financial interests.